Printer Friendly

SEARLE AND WYETH-AYERST TO CO-PROMOTE MAXAQUIN

 SEARLE AND WYETH-AYERST TO CO-PROMOTE MAXAQUIN
 PHILADELPHIA, July 20 /PRNewswire/ -- Searle and Wyeth-Ayerst today


announced an agreement to co-promote Searle's new quinolone antibacterial agent, Maxaquin(R) (lomefloxacin HC1), in the United States.
 "We are pleased with this partnership, which makes optimum use of our sales, marketing and scientific resources and will speed access and familiarity by physicians to Maxaquin," said Joseph T. Curti, M.D., president, Searle North American Operations. "Maxaquin represents the latest advance in anti-infective therapy. We are highly confident in the long-term contributions of the quinolone class in the treatment of infectious disease."
 "Wyeth-Ayerst is very enthusiastic about joining forces with Searle to co-promote Maxaquin, which has been successfully used worldwide with over six million prescriptions dispensed to date. We look forward to working closely with Searle to ensure a successful alliance. Our combined efforts will enable us to rapidly communicate important information about this unique anti-infective agent," stated Fred Hassan, president, Wyeth-Ayerst Laboratories.
 Maxaquin is the first one-tablet, once-a-day, broad spectrum quinolone antibiotic indicated for the treatment of complicated(1) and uncomplicated(a) urinary tract infections (UTIs) and acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae and Moraxella catarrhalis, the two most prevalent bacteria associated with this type of lower respiratory tract infection. Maxaquin is not indicated for empiric use when it is probable that this condition is caused by Streptococcus pneumoniae. Maxaquin is also the first oral antimicrobial agent indicated for prevention of UTIs in the three- to five-day period following transurethral surgery, such as prostate surgery.(2) Like other quinolones, Maxaquin is not for use in children under 18 years, or in pregnant or lactating women. Side effects include nausea, headache, dizziness and photosensitivity.
 Searle is a research-based pharmaceutical company that develops, manufactures and markets prescription pharmaceuticals worldwide in the areas of cardiovascular, gastrointestinal, anti-inflammatory, anti- infective and central nervous system. It is a wholly owned subsidiary of Monsanto Company (NYSE: MTC).
 Wyeth-Ayerst, a division of American Home Products Corp. (NYSE: AHP), is a major research-oriented pharmaceutical company with leading products in the areas of female health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti- inflammatory agents, vaccines and infant nutritionals. American Home Products Corp. is a worldwide manufacturer and marketer of prescription drugs, medical supplies and diagnostic equipment, over-the-counter medicines and food products.
 (1) For mild to moderate infections due to Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Citrobacater diversus and Enterobacter cloacae.
 (a) For mild to moderate infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Staphylococcus saprophyticus.
 (2) Not indicated for minor urologic procedures.
 The efficacy and safety of lomefloxacin in treating patients with Pseudomonas bacteremia has not been established.
 Maxaquin is a registered trademark of G.D. Searle & Co.
 -0- 7/20/92
 /CONTACT: Charles L. Fry, 708-470-6572, or Audrey Ashby, 215-971-5823, for Wyeth-Ayerst Laboratories/
 (MTC AHP) CO: G.D. Searle & Co.; Wyeth-Ayerst ST: Illinois, Pennsylvania IN: MTC SU:


PS -- NY073 -- 0870 07/20/92 15:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:493
Previous Article:GEORGIA-PACIFIC TAKES TEMPORARY DOWN TIME AT TWO COMMUNICATION PAPERS MILLS
Next Article:WINLAND ANNOUNCES PROFITABLE SECOND QUARTER
Topics:


Related Articles
SYNTEX RECEIVES APPROVAL FOR ADDITIONAL TORADOL IM SYRINGE SUPPLIER
WYETH-AYERST LABORATORIES AND THE LIPOSOME COMPANY ANNOUNCE FLU VACCINE AGREEMENT
BURROUGHS WELLCOME CO. AND WYETH-AYERST TO CO-PROMOTE NEW TREATMENT FOR CHICKENPOX
SEARLE AND WYETH-AYERST CO-PROMOTE ONLY ONCE-A-DAY QUINOLONE ANTIBIOTIC
WYETH-AYERST AND PANLABS SIGN RESEARCH COLLABORATION
WYETH-AYERST AND OPHIDIAN PHARMACEUTICALS TO DEVELOP IMPROVED ANTIDOTES FOR POISONOUS SNAKEBITE
WYETH-AYERST AND CYGNUS SIGN A MAJOR AGREEMENT FOR THE HORMONE REPLACEMENT MARKET
AFFYMAX N.V. ANNOUNCES STRATEGIC ALLIANCE WITH AMERICAN HOME PRODUCTS
Searle, Unimed Reach Agreement On U.S. Marketing And Distribution Rights For Maxaquin
Scios and Wyeth-Ayerst Terminate Co-Promotion Agreement for Antidepressant Drug, Effexor(R)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters